Webinar: Life Science Term Sheets

Over the past year, tech transfer directors from Columbia, Duke, JHU, Penn, MIT, Stanford, and Yale worked with life science VCs from 5AM, Atlas, Polaris, OUP, RA Capital, and Venrock to create a common set of principles for university startup deal negotiations. These principles were captured in two documents: “Recommendations for Term Sheet Structuring”, covering equity, royalties, milestones, sublicensing, know-how royalties, diligence, and other recommendations for creating win-win outcomes; and “Recommendations for Process Improvements”, with recommendations for structuring the negotiation process itself to avoid unnecessary friction, gain buy-in early, and avoid overly long and painful negotiations.

Webinar: Life Science Corporate Venture Capital

Corporate VCs have played a crucial role in financing life sciences companies for decades, but have you ever wondered what, if anything, makes them different from institutional venture capital funds? Join us for this webinar as we talk to a panel of investors at industry-leading CVC funds to learn more about their strategies, investment criteria, and how they measure success.

Biostar Biotech: Various Cap Table Scenarios for a Hypothetical Biotech Startup

Osage University Partners’ (OUP) Manager Partner Bill Harrington walks through various cap table scenarios of a hypothetical biotech university startup company called ‘Biostar Biotech.’

Bill highlights three different possible financial outcomes for this company’s investors and equity stakeholders, including a successful exit, a down round, and a company failure. A payout waterfall will be analyzed for each scenario, ending with a side-by-side returns comparison.

Webinar: Small Molecule vs Antibody Development Challenges

Therapeutics remain the primary focus for life science venture investments. As we all know, pre-clinical development of therapeutics is complicated, time consuming, and capital intensive. In the early stages of development, multiple aspects of a therapeutic product need to be optimized to enhance its drug-like properties. However, given the limited time and resources in the academic setting, what aspects of development should inventors focus on? Before diving into drug development, inventors should ask themselves: What is feasible in an academic setting? What is valued more by the investors? Should it be performed in-house or be out-sourced? How much would it cost?

2018 VC & University Startup Financing Trends

We’re almost halfway through 2018, which means we at Osage University Partners (OUP) again hosted our annual financing trends webinar (last year’s recap). For the 2018 version, our investment team analyzed not only general VC investment trends, but also trends specific to our partner university network of 5,000+ startups. I should mention this blog post only pulls…

Webinar: University In House Therapeutics Development

Recently, several universities and research institutions have set up internally driven and funded therapeutics development programs providing faculty the opportunity to push high impact translational research projects further than has been typically seen within an academic setting. These programs can oversee all stages of therapeutic discovery and development, from lab-based discovery to clinical trials. Why did these institutions decide to start these programs? How are these programs administered? What multi-disciplinary talent is needed and where did each institution find it? And perhaps most importantly, how much do these programs cost and who pays the bill?

Webinar: Diagnostics Startups

While investments in biotech have reached record highs in recent years, investment in the diagnostics sector from traditional VCs has cooled. This is despite a rapid decline in the cost of sequencing and increased public interest in the potential of precision medicine. In this webinar, Osage University Partners explores the unique challenges facing diagnostics with Garheng Kong, a Managing Partner at HealthQuest Capital, a LabCorp director and active diagnostics investor, and Doug Fisher, CBO of Sera Prognostics and partner at InterWest Partners, also active in diagnostics.

Webinar: Medical Device Startups

A lively discussion about the changing investment and development opportunities for early stage startups in the medical device sector. Osage University Partners briefly reviews investment activity from the past 15 years, followed by a conversation and Q&A with Mike Carusi of Lightstone Ventures and Hanson Gifford from The Foundry. Mike and Hanson have been active in the medtech space for many years and between them amount some of the largest exits the sector has seen. Our panelists cover current areas of investment interest, provide an informed analysis of global medical device market dynamics and trends, and offer their suggestions on how to advance university-originated medical device concepts, inventions, and companies.

What’s the Pulse on 2017 Midyear VC Investment?

Every few weeks, Osage University Partners hosts a webinar that dives into a specific technology sector with the intention of helping the technology commercialization professionals at our partner institutions better understand current market behaviors. We realize, however, that financing trends can dramatically shift in only one quarter. We’re past the midyear mark in 2017 and…

Is Med Tech Venture Investment Waning?

When Osage University Partners (OUP) first decided to host a conversation between venture investors on a specific industry sector, one topic clearly presented itself through suggestions from several of our academic partners: venture investment in the medical device sector. Recurring questions included: Where is investment occurring in the area of med tech? When should I…